pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jun 16·1 min read
save

Medicare to Cover Obesity Drugs for Adults 65+ Starting Next Month

Jun 16, 2026·read at STAT ↗RegulatoryPositive

Medicare will begin covering prescription weight‑loss medications for beneficiaries aged 65 and older starting next month, marking the first time the program includes such drugs.

The coverage is part of a temporary government initiative aimed at expanding access, though officials acknowledge it may be challenging to discontinue later. The move reflects broader efforts to address obesity among seniors.

The article also notes other policy developments, including the FDA’s decision to permit Colorado to import certain prescription drugs from Canada and Germany’s ongoing pricing reforms, underscoring a busy regulatory landscape.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, Germany’s pricing plans, and more”

read at STAT ↗
723 words · retrieved Jun 16
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVO4LILLY2ELI LILLY CONovo Nordisk IncPFIZERSanofi
drugs
Ozempic5Wegovy5Obesity4Wegovy Pill4Rybelsussemaglutide
topics
Obesity7Approval3OncologySmall MoleculeType 2 Diabetes

related stories

  • Jul 23Chutes & Ladders—Biogen R&D vet gets in FormationFierce Biotech
  • Aug 27Myriad catalysts on deck for obesity’s brightest stars as market continues to accelerateBioSpace
  • Aug 21Novo Nordisk starts trialing lower maintenance doses of oral WegovyBioSpace
  • Aug 19Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?BioSpace
  • Aug 5‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growthFierce Biotech